Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADI-PEG 20 with Nab-Paclitaxel and Gemcitabine in Advanced Pancreatic Cancer
NCT02101580Phase 1Completed
- Sponsor
- Polaris Group
- Start
- Nov 2014
- Primary completion
- May 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Pegargiminase in pancreatic cancer (PC), sponsored by Polaris Group. Primary endpoint: Number of Participants with Adverse Events as a Measure of Safety and Tolerability at 1 year. Started Nov 2014; status: completed.
02
Drugs
Pegargiminase
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT02101580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02101580.